BamSEC and AlphaSense Join Forces
Learn More

Myovant Sciences Ltd – Material Contracts

Formerly NYSE: MYOV
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.3
from 10-Q 12 pages Material contract
12/34/56
EX-10.2
from 10-Q 3 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. December 5, 2022 Re: Co-Promotion of Myfembree in Canada Under the Collaboration and License Agreement by and Between Myovant Sciences Gmbh (“Myovant”) and Pfizer Inc. (“Pfizer”), Dated as of December 26, 2020
12/34/56
EX-10.4
from 10-Q 3 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.3
from 10-Q 6 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 4 to Market Access Services Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 3 to Market Access Services Agreement
12/34/56
EX-10.1
from 10-Q 24 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Amended and Restated Manufacturing & Services Agreement by and Between Excella Gmbh & Co. Kg, and Myovant Sciences Gmbh. Effective Date: April 04, 2019 Restatement Date: April 2, 2021
12/34/56
EX-10.1
from DEFA14A 15 pages Voting and Support Agreement
12/34/56
EX-10.1
from 8-K 15 pages Voting and Support Agreement
12/34/56
EX-10.1
from 10-Q 5 pages To: Matt Lang From: Dave Marek, Chief Executive Officer (CEO) Date: April 15, 2021 Subject: Letter of Understanding - Expatriate Assignment Immigration Approval
12/34/56
EX-10.40
from 10-K 2 pages Non-Executive Director Compensation Policy of Myovant Sciences Ltd
12/34/56
EX-10.7
from 10-K 3 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 4 to License Agreement
12/34/56
EX-10.1
from 8-K 1 page First Amendment to Myovant Sciences Ltd. 2020 Inducement Plan
12/34/56
EX-10.3
from 10-Q 2 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 10-Q 12 pages Separation Agreement and General Release
12/34/56
EX-10.1
from 10-Q 10 pages Myovant Sciences, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Certain Information Identified by “[***]” Has Been Excluded From the Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.43
from 10-K 2 pages Non-Executive Director Compensation Policy of Myovant Sciences Ltd
12/34/56
EX-10.42
from 10-K 2 pages Material contract
12/34/56
EX-10.40
from 10-K 12 pages Myovant Sciences Ltd. Restricted Stock Unit Grant Notice
12/34/56
EX-10.35
from 10-K 11 pages Myovant Sciences Ltd. Restricted Stock Unit Grant Notice
12/34/56